Share This Link

Miosis is the constriction of the pupil, which is typically associated with cholinergic or parasympathomimetic agents rather than sympathomimetics. While miosis helps open the trabecular meshwork, increasing IOP is a deleterious effect that would exacerbate glaucoma pathology rather than treating the ocular hypertensive state effectively.

Pupillary constriction, or miosis, is primarily mediated by the parasympathetic nervous system acting on the muscarinic receptors of the iris sphincter. While decreasing IOP is the therapeutic goal for glaucoma, the mechanism of a sympathomimetic agent is specifically directed toward pupillary dilation rather than pupillary constriction.

Although sympathomimetics correctly cause mydriasis, the second part of this choice is clinically incorrect for a therapeutic intervention. Increasing intraocular pressure would result in optic disc cupping and irreversible visual field loss, which contradicts the entire pharmacological intent of administering anti-glaucoma eye drop medications.

Suggesting an appointment to discuss other medications is premature and ignores the primary assessment needed regarding the current drug's administration. Levothyroxine is the gold standard for thyroid replacement, and the nurse should first investigate lifestyle or timing factors that contribute to sleep disturbances before suggesting alternatives.

While rechecking the Thyroid Stimulating Hormone (TSH) level is a standard part of monitoring levothyroxine therapy, it is usually performed 6 to 8 weeks after initiation. Assessing the timing of the dose is a more immediate nursing intervention that can address the client's complaint of insomnia more efficiently.

Proposing a dose decrease without clinical evidence of toxicity or lab confirmation of suppressed TSH is outside the nursing scope of practice. The nurse must first gather subjective and objective data regarding how and when the medication is taken before recommending a change in the prescribed dosage.

Tetracycline therapy does not typically cause amenorrhea or the temporary cessation of menstrual cycles. Such reproductive changes are not documented side effects of this antibiotic class. Education should instead focus on the risk of secondary infections, such as vaginal candidiasis, which can occur due to altered flora.

Taking tetracycline with a large meal significantly impairs its absorption. Tetracyclines should ideally be taken on an empty stomach, at least 1 hour before or 2 hours after meals, to ensure maximum bioavailability and therapeutic serum levels are reached for the effective treatment of the skin condition.

Administering tetracycline with milk or dairy products is contraindicated because the drug undergoes CHELATION with calcium ions. This process forms insoluble complexes that the body cannot absorb, rendering the antibiotic ineffective. Patients must be warned to avoid dairy, antacids, and iron supplements within 2 hours of their dose.

Gastrointestinal bleeding is not a primary complication associated with the interaction between levodopa-carbidopa and MAO inhibitors. While levodopa can cause nausea or vomiting, the specific synergistic risk of combining these two classes of medications is cardiovascular in nature, specifically involving the sympathetic nervous system's response to catecholamine overload.

Fulminant liver failure is an acute loss of hepatic function not typically associated with the combination of levodopa and MAOIs. While some COMT inhibitors used in Parkinson's (like tolcapone) require liver monitoring, the immediate and most dangerous risk of the levodopa-MAOI interaction is the induction of a hypertensive emergency.

Respiratory depression is generally associated with central nervous system depressants such as opioids or benzodiazepines. The interaction between levodopa and MAO inhibitors is stimulatory rather than inhibitory. It results in a hyper-sympathetic state, which would more likely cause tachypnea and agitation rather than a decrease in respiratory drive.

Continuing to monitor without intervention is dangerous because muscle pain and dark urine are not "common" or benign side effects; they are "red flag" symptoms. Ignoring these signs can lead to permanent renal failure or death as the muscle necrosis progresses and releases toxic intracellular contents into the blood.

Recommending a lower dose is an inappropriate response to a potentially life-threatening drug toxicity. When rhabdomyolysis is suspected, the medication must be discontinued immediately. The nurse's priority is to ensure the patient is evaluated for organ damage rather than suggesting adjustments to a dangerous medication regimen.

While increasing fluids is a supportive treatment for myoglobinuria to protect the kidneys, it is not the primary nursing action. The nurse must first facilitate a medical diagnosis through laboratory testing of creatine kinase (CK) levels. Instructing the client to simply drink more water delays necessary emergency medical intervention.

Taking this medication right before bed is strictly contraindicated. The patient must remain in an upright position for at least 30 minutes following administration to prevent ESOPHAGEAL REFLUX. Recumbency shortly after ingestion increases the risk of the medication remaining in the esophagus, which can lead to severe erosive esophagitis or perforation.

This statement is pharmacologically incorrect. The absorption of bisphosphonates is significantly reduced—often to negligible levels—by the presence of food, minerals, or caffeine in the stomach. To achieve therapeutic serum levels, the drug must be administered in a fasting state to prevent interference from dietary cations like calcium.

Lying down immediately after dose administration is a dangerous practice for patients on alendronate. Post-dose UPRIGHT POSTURE is a mandatory safety requirement to ensure gravity assists the passage of the medication through the diaphragm and into the gastric environment, protecting the sensitive squamous epithelium of the esophagus from chemical burns.

Using a narrow-spectrum antibiotic for empiric therapy is generally avoided unless the pathogen is highly predictable. Narrow-spectrum agents target a limited range of bacteria; if the infecting organism falls outside that range, the therapy will fail, potentially leading to clinical deterioration of the patient while awaiting laboratory confirmation.

While carbapenems are broad-spectrum, they are typically reserved as "last-line" agents for multidrug-resistant organisms. Using them routinely for initial empiric therapy in all cases violates ANTIMICROBIAL STEWARDSHIP principles. Empiric choice should be guided by local antibiograms and the specific site of infection rather than using a one-size-fits-all carbapenem.

Restricting empiric therapy to only Gram-negative coverage is medically unsound unless the clinical presentation specifically points to such organisms. Most community and hospital-acquired infections can be caused by a mix of Gram-positive and Gram-negative bacteria; therefore, an effective empiric regimen must provide comprehensive, diversified antimicrobial activity.

Vitamin B12 deficiency causes megaloblastic anemia due to impaired DNA synthesis. The treatment for this condition is the administration of cyanocobalamin, not epoetin alfa. Administering an erythropoiesis-stimulating agent without addressing the underlying nutritional deficiency would be ineffective, as the marrow lacks the building blocks for healthy cell production.

Advanced osteoporosis with fractures involves skeletal mineralization defects and mechanical bone failure. While significant blood loss from a major fracture could theoretically lead to anemia, epoetin alfa is not a standard or indicated treatment for osteoporosis-related issues. Management focuses on bisphosphonates, calcium, vitamin D, and surgical stabilization.

Iron deficiency anemia is characterized by microcytic, hypochromic red blood cells and is treated with oral or parenteral iron supplementation. While iron is necessary for epoetin alfa to work effectively, epoetin alfa itself is not indicated as a primary treatment for dietary iron deficiency in the absence of chronic renal failure.

While adenosine has some indirect effects on calcium currents by antagonizing cyclic AMP, it is not classified as a calcium channel blocker. Medications like diltiazem or verapamil are the primary agents that inhibit L-type calcium channels to slow the heart rate, whereas adenosine's mechanism is distinct and much shorter-acting.

Adenosine does not increase cardiac contractility; in fact, its effect on the atria is negatively inotropic. Increasing contractility (positive inotropy) is a characteristic of catecholamines or phosphodiesterase inhibitors like milrinone. Adenosine's therapeutic utility is strictly related to its potent, albeit transient, dromotropic effect on the conduction system.

Prolonging the QT interval is a characteristic of Class IA and Class III antiarrhythmics, such as amiodarone or sotalol. Adenosine has an extremely short half-life of less than 10 seconds and does not cause significant prolongation of the QT interval. Its focus is the rapid termination of nodal re-entrant tachycardias.

D5 0.9% Normal Saline is a hypertonic solution. Administering a hypertonic fluid to a patient who is already hypernatremic would exacerbate the osmotic gradient, drawing even more water out of the cells and potentially worsening the neurological symptoms associated with severe cellular dehydration and elevated serum osmolality.

Lactated Ringers (LR) is an isotonic crystalloid solution. While it is excellent for volume expansion in trauma or surgery, it contains 130 mEq/L of sodium. In the context of a sodium level of 155 mEq/L, LR is not the optimal choice for correcting the free water deficit specifically needed to resolve hypernatremia.

0.9% Sodium Chloride, or Normal Saline, is an isotonic solution. Although its sodium concentration (154 mEq/L) is slightly lower than the patient's current level, it does not provide enough free water to effectively lower the serum sodium. It is generally used for ECF volume depletion rather than treating primary hypernatremic dehydration.